GNRH1 and posterior cortical atrophy: A Scottish Cancer Registry data analysis showed an increased CVD in patients treated with both GnRH antagonist (HR 1.5; 95% CI, 1.2–1.9) and GnRHa (HR 1.3; 95% CI, 1.2–1.4), compared with untreated patients with PCa; fewer patients were treated with GnRH antagonist than GnRHa, and there was limited adjustment for cancer stage [36].